Accessibility Menu
Intensity Therapeutics logo

Intensity Therapeutics(NASDAQ) INTS

Current Price$4.34
Market Cap$12.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-97%
5 YearN/A
1 Year-45%
1 Month+9%
Intensity Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.452026-07-24
Intensity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.32%USD 4.752026-07-17
1 month+9.07%USD 4.082026-06-24
3 month-15.24%USD 5.252026-04-24
Year to date-56.61%USD 10.262025-12-31
1 year-45.23%USD 8.132025-07-24
3 year-97.05%USD 150.752023-07-25
Since inception-97.01%USD 149.002023-06-30

Intensity Therapeutics Financials at a Glance

Market Cap

$12.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.69M

EPS (TTM)

-$7.08

P/E Ratio

-0.63

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$4.34

Volume

3,460.73

Open

$4.49

Previous Close

$4.45

Daily Range

$4.40 - $4.49

52-Week Range

$3.51 - $43.50

Estimated Earnings Date

Aug 6, 2026

INTS News

Foolcom-Featured.png

Intensity (INTS) Q2 Net Loss Drops 50%

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Intensity Therapeutics

Intensity Therapeutics, Inc. is a late-stage biotechnology company focused on developing localized cancer therapies that trigger systemic immune responses. Its innovative approach involves using the proprietary DfuseRxSM platform to enhance drug delivery and efficacy, particularly in cancer immunotherapy. By directly injecting drugs into tumors, the company aims to improve the immune system's ability to detect and combat cancer cells. Intensity Therapeutics is advancing its lead product candidate, INT230-6, through various clinical trials, targeting multiple cancer types and exploring combination therapies with leading checkpoint inhibitors.

Products and Services

INT230-6: Lead product candidate comprised of cisplatin, vinblastine sulfate, and a unique amphiphilic molecule.

DfuseRxSM Platform: Proprietary technology for enhancing localized drug delivery in cancer treatments.

Clinical Trials: Includes INVINCIBLE-3 Phase 3 study for soft tissue sarcoma and Phase 2 study for triple-negative breast cancer.

Strategic Partnerships: Collaborations with Merck, Bristol Myers Squibb, and Swiss Group for Clinical Cancer Research (SAKK).

What Makes Intensity Therapeutics, Inc. Special

Intensity Therapeutics stands out due to its approach of intratumoral drug delivery, which focuses on enhancing the immune system's ability to recognize and attack cancer cells. This technique aims to address challenges of traditional systemic therapies and offers a potential breakthrough in improved cancer treatment effectiveness and reduced toxicity.

Five Things You Need to Know

Intensity Therapeutics pioneered a unique drug delivery strategy that involves direct injection into tumors to enhance cancer therapy efficacy.

Its lead product, INT230-6, is undergoing a Phase 3 Trial for soft tissue sarcoma, with several other trials in progress.

The FDA has granted orphan drug designation to INT230-6 for treating soft tissue sarcoma.

INT230-6 has demonstrated tumor-killing capabilities and systemic immune activation in clinical trials.

The company has strategic partnerships with major pharmaceutical companies to further its research and expand its global reach.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Lewis H. Bender, MBA

Website

www.intensitytherapeutics.com

Headquarters

Shelton, CT 06880, US

INTS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-136.82%

Return on Capital

-99.88%

Return on Assets

-87.00%

Earnings Yield

-1.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.70M

Volume

3.46K

Avg. Volume

40.79K

Financials (TTM)

Gross Profit

-$7.00K

Operating Income

-$11.10M

EBITDA

-$7.95M

Operating Cash Flow

-$9.07M

Capital Expenditure

$0.00

Free Cash Flow

-$9.07M

Cash & ST Invst.

$10.25M

Total Debt

$102.00K

Intensity Therapeutics Performance Analysis

Intensity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Intensity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Intensity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -14.47-4.0%
20232023-12-31USD -34.42137.9%
20242024-12-31USD -29.24-15.0%
20252025-12-31USD -8.56-70.7%
Intensity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3040.9%
Q32025-09-3052.3%
Q42025-12-3121.9%
Q12026-03-3120.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$12.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$751.72K

N/A

Employees

16

N/A

Net Income

-$2.43M

+27.3%

EBITDA

-$2.43M

+27.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$10.25M

+1002.8%

Total Debt

$102.00K

-22.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$70.00K

-31.4%

Short Term Debt

$32.00K

+10.3%

Return on Assets

-87.00%

N/A

Return on Invested Capital

-1.10%

N/A

Free Cash Flow

-$1.83M

+8.2%

Operating Cash Flow

-$1.83M

+8.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NXTCNextCure, Inc.
$4.24+1.44%
PSTVPlus Therapeutics, Inc.
$3.83+1.32%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
PLURPluri Inc.
$1.78-0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About INTS

What is the current price of Intensity Therapeutics?

Intensity Therapeutics is trading at $4.45 per share.

What is the 52-week range for Intensity Therapeutics?

Over the past 52 weeks, Intensity Therapeutics has traded between $3.51 and $43.50.

How much debt does Intensity Therapeutics have?

As of the most recent reporting period, Intensity Therapeutics reported total debt of $102.00K.

How much cash does Intensity Therapeutics have on hand?

Intensity Therapeutics reported $10.25M in cash and cash equivalents in its most recent financial results.

What is Intensity Therapeutics’s dividend yield?

Intensity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services